Management of Hypertension in the Outpatient Setting

Primary Care - Clinics in Office Practice

Volumn 35, Issue 3, 2008, Pages 451-473

  Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS VALSARTAN; ATENOLOL; CAPTOPRIL; CHLORTALIDONE; CLONIDINE; DILTIAZEM; DOXAZOSIN; ENALAPRIL; ENALAPRIL MALEATE PLUS FELODIPINE; EPLERENONE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; MINOXIDIL; NATRIURETIC FACTOR; OLMESARTAN; PRAZOSIN; SPIRONOLACTONE; TELMISARTAN; TRANDOLAPRIL PLUS VERAPAMIL; VERAPAMIL;

ADD ON THERAPY; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIZZINESS; DROWSINESS; DRUG DOSE TITRATION; DRUG MEGADOSE; FATIGUE; GLUCOSE INTOLERANCE; HEADACHE; HEALTH CARE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; LIFESTYLE; MONOTHERAPY; OUTPATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; XEROSTOMIA;

AMBULATORY CARE; ANTIHYPERTENSIVE AGENTS; HEALTH PROMOTION; HUMANS; HYPERTENSION; LIFE STYLE; OUTPATIENTS; PATIENT EDUCATION AS TOPIC; PHYSICIAN-PATIENT RELATIONS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE;

EID: 49449086362     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pop.2008.05.002     Document Type: Review

References (76)

1. Burt V.L., Cutler J.A., Higgins M., et al. Trends in prevalence, awareness, treatment, and control of hypertension in the adult U.S. population: data from the health examination surveys, 1960-1991. Hypertension 26 (1995) 60-69
2. Patel B.V., Remigio-Baker R.A., Mehta D., et al. Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United States. J Clin Hypertens (Greenwich) 9 (2007) 692-700
3. Cushman W.C., Reda D.J., Perry H.M., et al. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 160 (2000) 825-831
4. Izzo J.L., Sica D.A., and Black H.R. Initial workup of adults with hypertension. In: Izzo J.L., Sica D.A., and Black H.R. (Eds). Hypertension primer. 4th edition (2008), Lippincott Williams and Wilkins, Philadelphia 343-347
5. Hansson L., Smith D.H., Reeves R., et al. Headache in mild-to-moderate hypertension and its reduction by irbesartan therapy. Arch Intern Med 160 (2000) 1654-1658
6. Verberk W.J., Kroon A.A., Kessels A.G., et al. Home blood pressure measurement: a systematic review. J Am Coll Cardiol 46 (2005) 743-751
7. Pickering T.G., Hall J.E., Appel L.J., et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 111 (2005) 697-716
8. O'Brien E., Asmar R., Beilin L., et al. European Society of Hypertension Working Group on Blood Pressure Monitoring. Practice guidelines of the European Society of Hypertension for Clinic, Ambulatory and Self Blood Pressure Measurement. J Hypertens 23 (2005) 697-701
9. Staessen J.A., Den Hond E., Celis H., et al. Treatment of Hypertension Based on Home or Office Blood Pressure (THOP) trial investigators. Antihypertensive treatment based on blood pressure measurement at home or in the physician's office: a randomized controlled trial. J Am Med Assoc 291 (2004) 955-964
10. Mengden T., Hernandez Medina R.M., et al. Reliability of reporting self-measured blood pressure values by hypertensive patients. Am J Hypertens 11 (1998) 1413-1417
11. Verberk W.J., Kroon A.A., Lenders J.W., et al. Home versus office measurement, reduction of unnecessary treatment study investigators. Self-measurement of blood pressure at home reduces the need for antihypertensive drugs: a randomized, controlled trial. Hypertension 50 (2007) 1019-1025
12. Giles T.D., Berk B.C., Black H.R., et al. Expanding the definition and classification of hypertension. J Clin Hypertens (Greenwich) 7 (2005) 505-512
13. Chobanian A.V., Bakris G.L., Black H.R., et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc 289 (2003) 2560-2572
14. White W.B. Importance of blood pressure control over a 24-hour period. J Manag Care Pharm 13 8 Suppl B (2007) 34-39
15. Patel P.V., Wong J.L., and Arora R. The morning blood pressure surge: therapeutic implications. J Clin Hypertens (Greenwich) 10 (2008) 140-145
16. Hermida R.C., Ayala D.E., Fernández J.R., et al. Comparison of the efficacy of morning versus evening administration of telmisartan in essential hypertension. Hypertension 50 (2007) 715-722
17. Protogerou A.D., Safar M.E., Iaria P., et al. Diastolic blood pressure and mortality in the elderly with cardiovascular disease. Hypertension 50 (2007) 172-180
18. Fagard R.H., Staessen J.A., Thijs L., et al. On-treatment diastolic blood pressure and prognosis in systolic hypertension. Arch Intern Med 167 (2007) 1884-1891
19. Jamerson K.A., and Basile J. Prompt, aggressive BP lowering in high-risk patients. J Clin Hypertens (Greenwich) 10 1 Suppl 1 (2008) 40-48
20. Izzo J.L., Sica D.A., and Black H.R. Barriers to blood pressure control. In: Izzo J.L., Sica D.A., and Black H.R. (Eds). Hypertension primer. 4th edition (2008), Lippincott Williams and Wilkins, Philadelphia 418-420
21. Rose A.J., Shimada S.L., Rothendler J.A., et al. The accuracy of clinician perceptions of "usual" blood pressure control. J Gen Intern Med 23 (2008) 180-183
22. Doran T., and Fullwood C. Pay for performance: is it the best way to improve control of hypertension?. Curr Hypertens Rep 9 (2007) 360-367
23. Sacks F.M., Svetkey L.P., Vollmer W.M., et al. DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med 344 (2001) 3-10
24. Fung T.T., Chiuva S.E., McCullough M.L., et al. Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women. Arch Intern Med 168 (2008) 713-720
25. Neaton J.D., Grimm Jr. J.H., Prineas R.J., et al. The treatment of mild hypertension study: final results. J Am Med Assoc 270 (1993) 713-724
26. Materson B.J., Reda D.J., Cushman W.C., et al. Department of Veterans Affairs single-drug therapy of hypertension study: revised figures and new data. Am J Hypertens 8 (1995) 189-192
27. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Hypertension 42 (2003) 239-246
28. Wykretowicz A., Guzik P., and Wysocki H. Doxazosin in the current treatment of hypertension. Expert Opin Pharmacother 9 (2008) 625-633
29. Turnbull F. Blood pressure lowering treatment trialists' collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362 (2003) 1527-1535
30. Turnbull F., Neal B., Algert C., et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 165 (2005) 1410-1419
31. Lindholm L.H., Carlberg B., and Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 366 (2005) 1545-1553
32. Sica D.A. Do pleiotropic effects of antihypertensive medications exist or is it all about the blood pressure?. Current Cardiovascular Risk Reports 1 (2007) 198-203
33. Sehgal A.R. Overlap between whites and blacks in response to antihypertensive drugs. Hypertension 43 (2004) 566-572
34. Messerli F.H., Grossman E., and Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. J Am Med Assoc 279 (1998) 1903-1907
35. White W.B., Johnson M.F., Black H.R., et al. Gender and age effects on the ambulatory blood pressure and heart rate responses to antihypertensive therapy. Am J Hypertens 14 (2001) 1239-1247
36. 1-adrenergic blockers: current usage considerations. J Clin Hypertens (Greenwich) 7 (2005) 757-762
37. Sica D.A. Angiotensin-converting enzyme inhibitors. In: Battegay E., Lip G., and Bakris G. (Eds). Handbook of hypertension. 1st edition (2005), Marcel Decker, Inc., New York 475-498
38. Sica D.A. Rationale for fixed-dose combinations in the treatment of hypertension: The cycle repeats. Drugs 62 (2002) 243-262
39. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the systolic hypertension in the elderly program (SHEP). J Am Med Assoc 265 (1991) 3255-3264
40. Wright Jr. J.T., Dunn J.K., Cutler J.A., et al. Outcomes in hypertensive black and non-black patients treated with chlorthalidone, amlodipine, and lisinopril. J Am Med Assoc 293 (2005) 1595-1608
41. Ernst M.E., Carter B.L., Goerdt C.J., et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 47 (2006) 352-358
42. Flack J.M., and Cushman W.C. Evidence for the efficacy of low-dose diuretic monotherapy. Am J Med 101 (1996) 53S-60S
43. Zillich A.J., Garg J., Basu S., et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 48 (2006) 219-224
44. Sica D.A., and Gehr T.W.B. Diuretic use in stage 5 chronic kidney disease and end-stage renal disease. Curr Opin Nephrol Hypertens 12 (2003) 483-490
45. Weinberger M.H., Roniker B., Krause S.L., et al. A selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 15 (2002) 709-716
46. Chapman N., Dobson J., Wilson S., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49 (2007) 839-845
47. Nishizaka M.K., Zaman M.A., and Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 16 (2003) 925-930
48. Menard J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol 217 (2004) 45-52
49. Sica D.A. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 10 (2005) 23-29
50. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 112 (2005) 1825-1852
51. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43 5 Suppl 1 (2004) S1-290
52. Schoolwerth A., Sica D.A., Ballermann B.J., et al. Renal considerations in angiotensin converting enzyme inhibitor therapy. A statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 104 (2001) 1985-1991
53. Vleeming W., van Amsterdam J.G., Stricker B.H., et al. ACE inhibitor-induced angioedema: incidence, prevention and management. Drug Saf 18 (1998) 171-188
54. Israili Z.H., and Hall W.D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med 117 (1992) 234-242
55. Hou F.F., Zhang X., Zhang G.H., et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354 (2006) 131-140
56. Flaa A., Aksnes T.A., Strand A., et al. Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials. Expert Rev Cardiovasc Ther 5 (2007) 451-461
57. Sica D.A. Pharmacotherapy review-part 2. Angiotensin-receptor blockers. J Clin Hypertens (Greenwich) 7 (2005) 681-684
58. Mancia G., Grassi G., and Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 24 (2006) 3-10
59. Doulton T.W., He F.J., and MacGregor G.A. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 45 (2005) 880-886
60. Kunz R., Friedrich C., Wolbers M., et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148 (2008) 30-48
61. Lakhdar R., Al-Mallah M.H., and Lanfear D.E. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 14 (2008) 181-188
62. ONTARGET Investigators, Yusuf S., Teo K.K., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
63. Sica D.A., and Black H.R. Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: Can angiotensin-receptor blockers be safely used?. J Clin Hypertens (Greenwich) 4 (2002) 375-380
64. Bakris G.L., Siomos M., Richardson D., et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. Kidney Int 58 (2000) 2084-2092
65. Sica D.A. Calcium channel blockers. J Clin Hypertens 8 (2006) 53-56
66. Gradman A.H. Treatment of hypertension with felodipine in patients with concomitant diseases. Clin Cardiol 16 (1993) 294-301
67. Agodoa L.Y., Appel L., Bakris G., et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. J Am Med Assoc 285 (2001) 2719-2728
68. Segura J., García-Donaire J.A., and Ruilope L.M. Are differences in calcium antagonists relevant across all stages of nephropathy or only proteinuric nephropathy?. Curr Opin Nephrol Hypertens 16 (2007) 422-426
69. Bakris G.L. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich) 10 1 Suppl 1 (2008) 27-32
70. Sica D.A. Calcium-channel blocker peripheral edema-Can it be resolved?. J Clin Hypertens (Greenwich) 5 (2003) 291-294 297
71. Goldstein S. β-Blockers in hypertensive and coronary heart disease. Arch Intern Med 156 (1996) 1267-1276
72. Fonarow G.C. Practical considerations of beta-blockade in the management of the post-myocardial infarction patient. Am Heart J 149 (2005) 984-993
73. Sica D.A. Old antihypertensive agents-diuretics and β-blockers-Do we know how and in whom they lower blood pressure. Curr Hypertens Rep 1 (1999) 296-304
74. Carlberg B., Samuelson O., and Lindholm L.H. Atenolol in hypertension: is it a wise choice?. Lancet 364 (2004) 1684-1689
75. Sica D.A., and Grubbs R. Transdermal clonidine: therapeutic considerations. J Clin Hypertens (Greenwich) 7 (2005) 558-562
76. Bakris G.L., Fonseca V., Katholi R.E., et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. J Am Med Assoc 292 (2004) 2227-2236